Noémie Desgagnés

Insulin edema is a rare complication of insulin therapy, typically occurring during treatment initiation or intensification. We report a 55-year-old woman with a longstanding diagnosis of type 2 diabetes (hemoglobin A1c 11.8% [4.3%-6.0%]) with low adherence to insulin therapy due to the rapid onset of peripheral edema and weight gain following insulin injections. Secondary etiologies of edema were ruled out, and she was diagnosed with insulin edema syndrome. Various types of insulin were tried, including an automated insulin delivery, which worsened her edema and weight gain, leading to discontinuation of all insulins. She was later diagnosed with latent autoimmune diabetes in adults. Weekly insulin icodec was introduced, which was well-tolerated by the patient and improved her adherence to therapy and her insulin edema without significant weight gain. Insulin edema is a diagnosis of exclusion, and clinicians should be aware of this clinical entity. The use of third-generation long-acting insulin analog may be helpful in some patients with this syndrome.

Objective: Onset and exacerbation of autoimmune, inflammatory or steroid‐responsive conditions have been reported following the remission of Cushing syndrome, leading to challenges in distinguishing a new condition versus expected symptomatology following remission. We describe a case of a 42‐year‐old man presenting with new‐onset sarcoidosis diagnosed 12 months following the surgical cure of Cushing syndrome and synthesise existing literature reporting on de novo conditions presenting after Cushing syndrome remission.Methods: A scoping review was conducted in Medline, Epub, Ovid and PubMed. Case reports and case series detailing adult patients presenting with new‐onset conditions following Cushing syndrome remission were included.Results: In total, 1641 articles were screened, 138 full‐text studies were assessed for eligibility, and 43 studies were included, of which 84 cases (including our case) were identified. Most patients were female (85.7%), and the median reported age was 39.5 years old (IQR = 13). Thyroid diseases were the most commonly reported conditions (48.8%), followed by sarcoidosis (15.5%). Psoriasis, lymphocytic hypophysitis, idiopathic intracranial hypertension, multiple sclerosis, rheumatoid arthritis, lupus and seronegative arthritis were reported in more than one case. The median duration between Cushing remission and de novo condition diagnosis was 4.1 months (IQR = 3.75). Of those patients, 59.5% were receiving corticosteroid therapy at the time of onset.Conclusion: Our scoping review identified several cases of de novo conditions emerging following the remission of Cushing syndrome. They occurred mostly in women and within the year following remission. Clinicians should remain aware that new symptoms, particularly in the first year following the treatment of Cushing syndrome, may be manifestations of a wide range of conditions aside from adrenal insufficiency or glucocorticoid withdrawal syndrome.

In high-income, low-prevalence settings, travel patterns largely govern malaria transmission; the COVID-19 pandemic has led to travel restrictions resulting in a decrease in malaria case incidence. The proportion of travellers seeking pre-travel has decreased; with the easing of borders, an increase in malaria cases may occur.